Enhance your practice with CME and tools that focus on the management of neurological conditions.
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Aaron Miller, MD
Challenging the Status Quo in Schizophrenia Treatment
Shelina Ramnarine, PhD
Stephen Marder, MD
The Social Brain in Schizophrenia
Michael Green, PhD
Emerging Serum microRNAs as Early Signals in MS
Advancing Pediatric MS Care: Insights from AAN 2026
Elizabeth Wilson, MD
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Turning Flares Into Function: Flag Uncontrolled Disease
Minimal By Design: Define MSE Endpoints
Escalate With Intention: Stepwise, Target-Anchored Moves
Shared Goals, Shared Gains: Align With Patient Preferences
Target Locked in gMG: Why T2T Matters
Updates in MS Care: Key Topics at AAN 2026
Nutrition and the Gut-Brain Connection in Schizophrenia
Deanna L. Kelly, PharmD, BCPP
Family Planning in Patients with Multiple Sclerosis
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Addressing Social and Systemic Barriers in Schizophrenia
Margaret Emerson, DNP, APRN, PMHNP-BC
Depression as a Signal of MS Progression
When to Begin FcRn: Initiation Criteria, Key Evidence
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Loading...
We're glad to see you're enjoying Global Neurology Academy… but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.